BioSpace News Archive

Ventus Therapeutics is presenting data for its cyclic GMP-AMP synthase (cGAS) inhibitor program this month at two upcoming conferences: the 4th Inflammatory Skin Disease Summit (November 3-6, 2021) and the American College of Rheumatology Annual Meeting, ACR Convergence (November 5-9, 2021).

Kezar Life Sciences, Inc. today announced that it will host a virtual Investor and Analyst Day on November 15, 2021, at 4:30 p.m. ET.

Minerva Neurosciences, Inc. today announced that the U. S. Food and Drug Administration (FDA) has denied the company’s request for a pre-NDA meeting for roluperidone and responded that a Type C guidance meeting would be more appropriate to discuss the evidence for use of roluperidone as monotherapy.

Autobahn Therapeutics today announced new preclinical data highlighting the company’s thyroid hormone-targeted approach to precisely deliver tailored therapeutics to the brain for the treatment of a range of CNS disorders.

The Parker Institute for Cancer Immunotherapy and the Cancer Research Institute announced the dosing of the first patients in the REVOLUTION trial, a phase I, open label platform study of novel immunotherapy combinations for first-line treatment of metastatic pancreatic cancer.

ENYO Pharma today announced that two abstracts on Vonafexor were accepted one as oral presentation and one as poster during the upcoming The Liver Meeting® 2021, organized by the American Association for the Study of Liver Diseases (AASLD) on November 12-15, 2021.

Rafael Pharmaceuticals, Inc., a company focused on the growing field of cancer metabolism-based therapeutics, announced that the European Medicines Agency has granted orphan drug designation to CPI-613® for the treatment of Burkitt’s lymphoma.

Prime Therapeutics LLC (Prime), a leading pharmacy benefit manager (PBM) serving nearly 33 million members, will be preferring Viatris’ biosimilar Semglee® (insulin glargine-yfgn, the branded product) injection and Insulin Glargine (insulin glargine-yfgn, the unbranded product) injection, co-developed with Biocon Biologics, on its national formularies as part of the pharmacy benefit.

Standigm Inc. (“Standigm”), announced today that the company had filed PCT (“Patent Cooperation Treaty”) patent application covering AI-driven repurposed drugs for primary mitochondrial disease through successful research collaboration with a US hospital, which has world-renowned expertise in the mitochondrial field.

Aditxt, Inc. (Nasdaq: ADTX), (“Aditxt” or the “Company”) a biotechnology innovation company with a mission to improve the health of the immune system, announced today a partnership with CLX Health, a developer of cloud-based solutions.